NCT01232894 - 12-week Open-label Evaluation of Efficacy and Safety of Indacaterol | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

Indacaterol

Indacaterol 150 µg once-daily via single-dose dry powder inhaler

DRUG

Long-acting beta2-agonist

Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily

Trial Locations (8)

Novartis Investigative Site, Afula

Novartis Investigative Site, Ashkelon

Novartis Investigative Site, Holon

Novartis Investigative Site, Jerusalem

Novartis Investigative Site, Kfar Saba

Novartis Investigative Site, Petah Tikva

Novartis Investigative Site, Rehovot

Novartis Investigative Site, Tel Aviv